CAR-T comes of age?
Thursday, October 14, at 1:00 p.m. ET / 10:00 a.m. PT
It’s been almost a decade since the release of the first stunning data on a cell therapy that battled blood cancer by genetically altering a patient’s own white blood cells to attack it.
Many years and billions of dollars in mergers and acquisitions later, CAR-T is still used mostly as a last resort. Could new clinical trials that are about to report out in full change that?
STAT looks ahead at what might happen.
- Daina Graybosch, Ph.D., senior research analyst at SVB Leerink
- Adam Feuerstein, senior writer, biotech, STAT (moderator)
- Anshul Mangal, president, Project Farma and Precision ADVANCE (sponsor speaker)
* The views expressed on this webinar by the SVB Leerink Research Analyst are as of the date of this recording and are subject to change. For disclosures specific to companies in the SVB Leerink Universe of Coverage, please go to the Equity Research page on svbleerink.com.